Abstract: Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).

Abstract: Apparatus for measuring forces on a load-carrying element comprises optical sensors mounted to the load-carrying element. Each optical sensor includes a light source, a photosensor and an opaque mask positioned in a light path between the light source and the photosensor. The mask has a window that is movable relative to the photosensor and is located such that light from the light source that passes through the window forms an illuminated region on the photosensor. Each of the optical sensors has a first part which includes the light source and the photosensor that is coupled to the load-carrying element at a first location and a second part that includes the mask that is attached to the load-carrying element at a second location spaced apart from the first location.

Abstract: A reactor that operates with ultraviolet light emitting diodes (UV-LEDs) to attain UV photoreactions or UV photo-initiated reaction in a fluid flow for various applications, including water purification. The UV-LED reactor is comprised of a conduit means for passing fluid flow, an ultraviolet light emitting diode (UV-LED), and a radiation-focusing element to focus the UV-LED radiation to the fluid in the longitudinal direction of the conduit. The UV-LED reactor may include photocatalysts or chemical oxidants, which are activated by UV emitted by UV-LEDs for photocatalytic and photo-initiated reactions.

Abstract: Provided herein are perfusion fluids for enzymatically cleaving A-antigens from a donor organ, and methods. uses. associated therewith. In particular, the perfusion fluids comprise two enzymes. GalNAcDeacetylase and Galactosaminidase and the fluids may further comprise a buffered extracellular solution and/or a crowing agent. Furthermore. the compositions described herein were found to have activity at temperatures and ph levels suitable for cell viability.

Abstract: A “frequency shifter” is a clock synthesis system, that includes either a multiplexer or a multi-modulus divider (MMD), a fractional frequency divider, a tunable delay element, a sawtooth signal generator, in addition to other synchronization and control circuits. The generated sawtooth signal is used to control the delay of the tunable delay element, which in turn is used to adjust the phase of the signal generated by either M-to-1 multiplexer or the MMD, reducing its timing errors, and improving the spectral purity of the generated clock signal.

Abstract: Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

Abstract: Provided herein are ?-1,3-linked biopolymers (acholetin polysaccharides). Furthermore, provided herein are enzymatic methods and systems for producing ?-1,3-linked oligosaccharides and polysaccharides using ?-1,3-N-acetylglucosaminide phosphorylase (Acholetin phosphorylase (AchP)). The AchP was sourced from the genome of the cell wall-less Mollicute bacterium, Acholeplasma laidlawii and was found to synthesize ?-1,3-linked N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) oligomers using the donor. ?-N-acetylglucosamine 1-phosphate (GlcNAc1-P) or N-acetylgalactosamine 1-phosphate (GalNAc1-P).

Abstract: The present invention provides an in vitro method, and in vitro assay, for staging, classification, screening, monitoring, stratification, selecting treatment for, ascertaining whether treatment is working in, and/or prognostication of cancer in a subject comprising determining allelic imbalance and copy number of target gene-regions in tumor DNA from a subject as set out in the application. The present invention also provides a set of oligonucleotide probes and kits for use in the method, and assay, of the present invention.

Abstract: Light reflective films have example application in hollow light guides and luminaires. The films comprise parallel channels distributed in layers or otherwise at different depths in the films. The channels provide interfaces at which light is reflected or redirected. The channels have a sufficient density that the film reflects a large proportion of light incident on a first face of the film. The channels may be filled with a gas such as air, a vacuum or a polymer for example. Methods for making films can include stacking thin sheets patterned with grooves, casting or extrusion.

Abstract: The disclosure pertains to antibodies that bind A-beta oligomers and methods of making and using said antibodies.

Abstract: A method for refining lithium from a crude brine includes charging a crude brine into a feeder tank held at a temperature T1 and containing a sufficient carbonate source to precipitate all carbonate-forming solids in the crude brine to form a precipitate mixture and a crystal free supernatant; pumping the crystal free supernatant from the feeder tank to a first crystallization reactor that is held at a temperature T2 to crystallize a lithium carbonate salt out of the crystal free supernatant; wherein the temperature T1 is lower than the temperature T2; and controlling a flow rate to maintain a steady state concentration of the lithium carbonate salt in the solution phase of the crystallization reactor.

Abstract: The present disclosure relates to methods for classifying a subject into a sepsis mechanistic endotype as well as methods for predicting severity of sepsis in a subject. The methods can comprise use of a biological sample obtained from the subject at first clinical presentation. The classification of the subject into a sepsis mechanistic endotype and/or prediction of severity of sepsis may, for example, allow for treatment of sepsis using an approach suitable to the particular mechanistic endotype and/or severity.

Abstract: The present invention relates to an expression vector that encodes all or a portion of replicon proteins from a positive stranded virus, wherein expression of the replicon proteins is under the control of CMV and T7 promoters, and wherein expression of a payload is under the control of a sub-genomic promoter. Also provided are methods of using the vector in therapeutics and vaccines.

Abstract: A method of beamforming by which a signal can be received into an array of channels, each of which is split into a real-part sub-channel and an imaginary part sub-channel. In each sub-channel, optical waves are used to carry the signal via waveguides. Each channel includes a real-part sub-channel where an optical wave is scaled by the real part of a complex number, and an imaginary part sub-channel, where a complementary optical wave is scaled by the complex part of the same complex number. When the complementary optical waves are received at the channel's output, they can be shifted by the phase of the complex number having defined their scaling. By processing a signal with a system operative to perform such method, the application of a different phase to each channel can result in a beamforming of the signal.

Abstract: A control system for administration of a drug comprises a drug administration actuator for administering the drug to a patient at a controllable dosage; a monitor for measuring an effect of the drug on the patient; and a controller configured to determine a control signal to the drug administration actuator; wherein the controller is configured to implement a closed loop model-predictive control scheme comprising, for each of a series of time steps, minimizing a cost function subject to one or more constraints to determine the control signal, the cost function based at least in part on a reference level and the monitor measurement; wherein the control signal is used as an input to an auxiliary model to estimate at least one concentration level of the drug in the patient; and wherein the constraints comprise at least one constraint on the estimate of the concentration level of the drug.

Abstract: Systems and methods for intermedullary bone fracture fixation are described herein. The fixation device includes a main body having a flexible state and a rigid state. The fixation device further includes a proximal interface coupled to a proximal end of the main body to anchor the fixation device to an exterior surface of the bone and a distal interface coupled to a distal end of the main body to anchor the fixation device to an interior cavity of the bone. The fixation device further includes a locking interface to configured to convert the main body from the flexible state to the rigid state.

Abstract: A variable thermal insulation assembly includes a plurality of sheets of film, wherein each sheet is bonded to an adjacent sheet along a plurality of longitudinally extending regions to form a plurality of longitudinally extending cavities, wherein the plurality of flexible sheets of each of the thermal cell arrays are formed of an electrically insulative material that is coated on one side with an electrically conductive material, a controller electrically coupled to the plurality of flexible sheets and configured to apply an electric potential difference between electrically conductive material of each pair of flexible sheets such that the electrically conductive coatings of the pair of flexible sheets attract each other to cause the thermal cell array to transition from an expanded state to a compressed state.

Abstract: Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers selected from one or more of: prostate cancer, breast cancer, colon cancer, cervical cancer, small-cell lung carcinomas, neuroblastomas, osteosarcomas, glioblastomas, melanoma and myeloid leukaemia.

Abstract: Processes and apparatus for electrocatalytically converting carbon dioxide emissions and/or ambient carbon dioxide into useful chemicals are described. The process may include: removing carbon dioxide from ambient air through a carbon capture technique, supplying a carbonate or bicarbonate aqueous solution as cathode feed to a cathode of an electrolytic cell comprising a membrane electrode assembly which includes a bipolar membrane separating an anode from the cathode, and applying an electrical potential difference between the cathode and the anode of the membrane electrode assembly to electrocatalytically reduce the carbonate or bicarbonate aqueous solution to carbon monoxide or another useful chemical.

Abstract: Provided herein are pharmaceutical dosage forms for delivering peptide therapeutics to a mucosal surface. The pharmaceutical dosage forms comprise a mucoadhesive layer; a peptide loading layer; and a water impermeable layer, wherein the peptide loading layer is between the mucoadhesive layer and the water impermeable layer, such that the water impermeable layer facilitates unidirectional movement of the encapsulated peptide through the mucoadhesive layer and to the target mucosal surface. The pharmaceutical dosage form is suitable for delivery of the encapsulated peptide therapeutic to buccal mucosa; sublingual mucosa; palate mucosa; and tongue mucosa. The peptide therapeutic may be an insulin; an insulin derivative; an insulin analog; a pre-insulin; a pro-drug of insulin; a glucagon-like peptide 1 (GLP-1); a GLP-1 analog; a pre- GLP-1; a pro-drug of GLP-1; or a combination thereof and may be suitable for the treatment of diabetes.